The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.
January 31st 2023
The real-world oncology data and analytics company COTA has joined the Clinical Research Data Sharing Alliance, a nonprofit consortium that aims to accelerate progress in cancer therapy development.
Concurrent Antibiotics, Steroids Raise CDI Risk in People With Lung Cancer Receiving EGFR-TKIs
January 9th 2023The new report found no evidence that second-generation tyrosine kinase inhibitors (TKIs) were more likely to lead to Clostridioides difficile infection (CDI) in patients with lung cancer.
Read More
Tumor-Associated Autoantibodies Demonstrate Promise as Immunotherapy Biomarkers in NSCLC
January 5th 2023The development of 2 panels measuring levels of tumor-associated autoantibodies (TAAbs) has promise for predicting therapeutic response and adverse events for patients with advanced non–small cell lung cancer (NSCLC) after immune checkpoint inhibitor–based treatment.
Read More
Administering Antimicrobial Therapy Before CIT May Be Safer Option in NSCLC
January 5th 2023This study investigated the effects of antimicrobial therapy among patients with non–small cell lung cancer (NSCLC) who received immunotherapy with a checkpoint inhibitor or chemotherapy plus immunotherapy (CIT).
Read More
Cannabis Used With ICIs Appears to Have No Impact on NSCLC Outcomes
December 7th 2022Differences in overall survival between cannabis users and those who did not use the plant were small and could be explained by differences in the make-ups of the 2 cohorts of patients with non-small cell lung cancer, researchers said.
Read More
Despite Improvements in Lung Cancer Screening, Increased Efforts Still Needed to Address Disparities
November 16th 2022The State of Lung Cancer 2022 report issued by the American Lung Association illustrates aspects of diagnosis and care that require additional attention to address disparities and increase nationwide screening and treatment engagement while reducing risk factor exposure.
Read More
Doubling Women’s Lung Cancer Research Funding Would Generate Major Returns, Study Says
November 13th 2022Lung cancer is the number one cause of cancer-related deaths among women in the United States, yet relatively little research funding is spent on the issue, the authors of a new study say.
Read More
Most Patients in China With Lung Cancer Experience Financial Toxicity
October 3rd 2022A new report finds despite reforms to the country’s health care system, many patients in China with lung cancer experience stress, and sometimes health consequences, on account of the disease’s financial burden.
Read More
Expensive Targeted Lung Cancer Therapies Need to Be Tailored to the Right Patient
September 29th 2022Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Read More
Dr Hatim Husain Discusses HER2, Novel Therapy Exploration in Lung Cancer
September 23rd 2022During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.
Read More
Phase 3 Trial Backs First-line Use of Cemiplimab With Chemotherapy in aNSCLC
September 21st 2022With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.
Read More
Real-world Lung Cancer Testing Rates Are Lower Than They Should Be, Says Dr Ticiana Leal
September 14th 2022Biomarker testing should be done on all patients with an initial diagnosis of advanced nonsquamous non–small cell lung cancer, but the testing rates in the real world are lower than they should be, particularly for underserved or minority populations, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Read More
Recommendations to Safeguard Quality Shared Decision-Making for Lung Cancer Screening
September 8th 2022An updated national coverage determination from CMS about lung cancer screening has some stakeholders concerned that the quality of decision-making tools used by providers and patients may weaken.
Read More
Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC
August 29th 2022Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.
Read More
Clinicians Slow to Adopt PD-1, PD-L1 Inhibitors in NSCLC
August 23rd 2022A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.
Read More
HER2m NSCLC an “Exciting Area of Active Investigation,” Says Dr Ticiana Leal
August 17th 2022Results from DESTINY-Lung01 have shown promising progression-free survival and overall survival with ongoing research that may lead to a future FDA approval in non–small cell lung cancer (NSCLC), said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Read More